1. Scrip
  2. >>Business
  3. >>Financing

ADC Therapeutics Raises $76m To Keep ADC Development Momentum Going

 
• By Mandy Jackson

The company extended its series E financing to $276m to keep its two lead ADC candidates moving toward pivotal data and BLA filings, including a planned filing for ADCT-402 late next year. The funding news comes as the ADC field moves into the spotlight.

Stack-100 bills
ADC Therapeutics has raised $531m since 2011 • Source: Shutterstock

Positive data and a drug approval have put antibody-drug conjugates (ADCs) into the spotlight recently and a new $76m financing announced 12 June by the Swiss firm ADC Therapeutics SARL underscores the field's growing momentum.

Lausanne-based ADC Therapeutics extended its $200m series E venture capital round, which originally closed in October 2017, to $276m. The...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Financing

Finance Watch: Braveheart Launches With $185m To Start Late-Stage Trials

 
• By Mandy Jackson

Private Company Edition: Braveheart Bio licensed its selective cardiac myosin inhibitor from Hengrui. Also, Arena BioWorks shuts down after raising $500m in 2024, GHO Capital closed a €2.5bn ($2.9bn) private equity fund and new cash brings Tubulis’s series C to €344m ($401m).

Biopharma Financial Market Recovery Has Legs As M&A Tally Climbs Higher

 
• By Mandy Jackson

Lower interest rates, M&A activity and a string of positive clinical trial readouts have boosted biopharma investor sentiment in a recovery that appears sustainable, according to William Blair healthcare capital markets managing director Kevin Eisele.

AAVantgarde Adds To Eye Disease Gene Therapy Trend With $141m Fundraising

 
• By Andrew McConaghie

While other gene therapies disease areas have fallen out of favor, eye disease candidates seem to be attracting more funding. Italy-based AAVantgarde is the latest to achieve a mega-round.

Finance Watch: MapLight Brings US Biopharma IPO Tally To 11 In 2025

 
• By Mandy Jackson

Public Company Edition: MapLight grossed $288.4m plus $8.1m from a private placement to fund neuropsychiatry clinical trials. Also, Evommune set a price range for its pending IPO of up to $183.3m, Sanofi priced a $3bn bond issue and Arcus raised $250m in a follow-on offering.

More from Business

Aurobindo On Easier US Biosimilar Pathway, Zentiva Miss And Deal Strategy

 
• By Vibha Ravi

Do US FDA’s efforts at simplifying the biosimilar pathway create more competition and threaten Aurobindo Pharma's return on investments? Management speaks on this, biosimilar filing plans and deal strategy at the Q2 FY26 earnings call

Korean Biosimilars Giants Step Up Race To Become Innovators

 
• By Jung Won Shin

South Korea’s two biosimilars giants have laid out differing strategies to pursue innovative drug R&D, although both are positioning ADCs as a core focus.

AstraZeneca Stays Coy On US Pricing Deal Impact

 
• By Andrew McConaghie

Another strong quarter keeps AstraZeneca on track to meet its $80bn sales ambition, and its CEO maintains the recent Trump deal provides pricing reassurance, despite a lack of details so far.